Grand Health Industrial

Grand Pharmaceutical Group, formerly known as China Grand Pharmaceutical and Healthcare Holdings, is a leading international pharmaceutical company headquartered in China and listed on the Hong Kong Stock Exchange (0512.HK). The company operates a diversified business model focusing on three core pillars: pharmaceutical technology, nuclear medicine anti-tumor diagnosis and treatment, and cerebro-cardiovascular precision interventional technology. Grand Pharma has established a robust global presence through strategic partnerships and acquisitions, notably in the field of Radionuclide Drug Conjugates (RDCs) with partners like Telix Pharmaceuticals and ITM. Its extensive portfolio includes innovative drugs, high-end medical devices, and active pharmaceutical ingredients (APIs) across therapeutic areas such as oncology, ophthalmology, ENT, and cardiovascular care. With a strong emphasis on R&D and internationalization, the company continues to expand its pipeline of first-in-class and best-in-class products to address unmet medical needs globally.